The “2022 United States Glaucoma Atlas” features updated analysis and estimates for glaucoma treatment opportunity in 85 US metropolitan areas. This new atlas includes updated counts of doctors offering MIGS and canal-based procedures and also features breakouts of cataract surgeons by volume category—with a new ultra-high category.
The 2022 atlas now includes a new metro interface in Excel format, which allows users to aggregate all metrics by state and region, and to quickly sort by metro.
The “2022 United States Glaucoma Atlas” provides a geographic analysis of the glaucoma population and treatment opportunity in 85 US metropolitan areas. Market Scope’s proprietary MedOp Index Analysis™ analyzes market potential and provides a benchmark against other atlas metros. The atlas offers strategic insights into the top potential markets in the US, which companies often use throughout the development and commercialization processes to identify ideal clinical trial locations, develop launch strategies, define sales territories, allocate resources, and optimize sales and marketing initiatives.
The atlas offers an in-depth examination of the glaucoma patient population, and Market Scope’s MedOp Index Analysis™ integrates all variables to illustrate US market opportunity by metro area. The following information is included for 85 metropolitan areas:
Geographic opportunity is estimated with multi-factor criteria using Market Scope’s MedOp Index™ Analysis. The index is derived from multiple supporting indexes and considers the following factors in each metro:
1 licensing type is available for this report:
The license includes an electronic PDF. Printed copies may be purchased for an additional $250.
SINGLE USER LICENSE
ENTERPRISE LICENSE
Pay by credit card or by invoice.
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.